DCPH
Deciphera Pharmaceuticals Inc
A maker of targeted cancer medicines, Deciphera develops drugs that switch off malfunctioning enzymes called kinases that help tumors grow. Its approved medicine QINLOCK treats gastrointestinal stromal tumors (GIST), and it became part of Japan's ONO Pharmaceutical group in 2024. Founded in 2003 by medicinal chemist Daniel Flynn, the company takes its name from "decipher," reflecting its mission to decode the complex biology of kinase enzymes. Its drugs are built on a "switch-control" platform that targets a pocket on the enzyme, a quirk of design that sets its approach apart.
CUSIP: 24344T101HealthcareUS2 holders